Project: Sensitive Screening in Treatment of Skin Cancer
We will improve companion diagnostics and monitoring of acquired drug resistance of malignant melanoma (MM) patients, ensuring better response to treatment and reducing use of inefficient therapies. This will be accomplished using our proprietary DNA platform, product development and clinical experiences. The resulting CE certified products will be included in a workflow with a DNA extraction platform and co-marketed by large biotech Promega and tested by end-users on >300 patient samples.
Acronym | SensiScreen Skin (Reference Number: 10440) |
Duration | 01/10/2016 - 01/10/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |